Harmony Biosciences Holdings, Inc.HRMY

Harmony Biosciences Holdings, Inc. just dropped a revenue bombshell: unaudited second-quarter 2026 net product revenue for WAKIX® (pitolisant) hit approximately $261 million, a quarterly record and up 30% year over year. The company also confirmed it’s on track to meet its full-year 2026 revenue guidance of $1.0 billion to $1.04 billion, based on first-half performance and current trends. The filing didn’t just brag-it spelled out the single-product reality that underpins the numbers. (source: Press release, 2026-07-16, https://www.sec.gov/Archives/edgar/data/1802665/000110465926084095/hrmy-20260716xex99d1.htm)

WAKIX is Harmony’s only commercial product, approved in the US for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company isn’t chasing blockbuster breadth; it’s doubling down on a niche sleep medicine with a clear label and a focused sales force. That focus is both its strength and its single-point risk: if demand wobbles, the entire revenue story wobbles with it. The product page and media resources confirm the company’s product-centric narrative, but they don’t prove patient uptake or payer persistence. (source: Our Products at Harmony Biosciences, https://www.harmonybiosciences.com/our-products/; Harmony Biosciences Media Resources, https://www.harmonybiosciences.com/newsroom/)

Behind the revenue headline, the company’s 10-Q for the quarter ended 31 March 2026 shows net income of $32.5 million on revenue of $215.4 million, an operating income of $37.3 million, and cash and cash equivalents of $589.4 million. The balance sheet looks healthy: total assets of $1.27 billion sit against liabilities of $361.5 million, leaving stockholders’ equity at $910.3 million. R&D spend clocked in at $69.4 million for the quarter, while capital expenditure was a rounding error at $128,000. Inventory sat at $5.3 million, broadly flat versus the prior quarter, and operating cash flow provided $27.8 million. Diluted EPS was $0.55 on 58.8 million shares. (source: SEC 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1802665/000110465926084095/hrmy-20260331.htm)

The filing also reveals a CFO transition and a separation agreement with former president Glenn Reicin, whose legal fees the company agreed to reimburse up to $10,000. It’s not a golden parachute, but it’s a reminder that leadership changes often leave filing trail trails behind the revenue headlines. The company’s SEC submissions index shows multiple Form 144 filings in late June and early July, suggesting insiders were testing the exit gates at the same time the revenue story hit new highs. (source: SEC submissions JSON, https://data.sec.gov/submissions/CIK0001802665.json; Separation Agreement, 2026-07-16, https://www.sec.gov/Archives/edgar/data/1802665/000110465926084095/hrmy-20260716xex10d1.htm)

There’s no public chart rail for HRMY in the evidence pack, so we’ll leave the candlesticks to the platforms that sell them. The company’s story is best read through its filings and product rails: one drug, one revenue engine, one guidance band. The tension isn’t in the math-it’s in the concentration. If the patient pool for WAKIX drifts or payers tighten, the entire edifice wobbles. If the company adds a second product or a new label, the story changes overnight. Until then, the file reads like a focused biotech story with quiet exits and a single product carrying the load. (source: SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001802665.json)

The evidence doesn’t parse share buybacks, buyback authorisations, or insider trading beyond the Form 144 notices. It also doesn’t prove the durability of payer coverage, patient persistence, or the timing of any future label expansion. What would deepen the file is a detailed breakdown of WAKIX’s payer mix, net revenue per prescription, and any upcoming label expansions or pipeline readouts. Until those arrive, the file is a clean but narrow story: a niche drug, a revenue record, and a balance sheet that looks healthy-for now. (source: Official product/news rail, https://www.harmonybiosciences.com/our-products/; SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1802665)